BioNTech SE Revenue & Financials

For the fiscal year ended December 31, 2024, BioNTech SE reported total revenues of $2998.7 million ($3.0 billion at average 2024 EUR/USD exchange rate of approximately 1.09), representing a 28.0% decline from $4162.7 million in 2023 and an 84.1% decline from the peak of $18868.6 million in 2022. The revenue contraction was entirely attributable to declining COVID-19 vaccine sales, with Comirnaty-related revenues falling from $4116.1 million in 2023 to $2651.0 million in 2024—a 35.6% decrease. Other revenues increased to $347.7 million (12% of total) from $46.7 million in 2023, primarily from the German Federal Ministry of Health pandemic preparedness contract. The company reported a net loss of $725.2 million for 2024, swinging from net profit of $1014.0 million in 2023. On a per-share basis, this translated to diluted loss per share of $3 ($3.00), compared to diluted earnings per share of $4.2 in 2023. The operating loss was $1765.7 million on a BioNTech SE standalone basis, and the consolidated operating result was similarly negative. Gross profit on a consolidated basis was $2408.7 million ($2998.7 million revenues minus $590.0 million cost of sales), yielding a gross margin of 80.3%. This margin is inflated by the collaboration accounting structure, where Pfizer's profit share is recorded as cost of sales rather than revenue reduction. Research and development expenses surged 26.4% to $2457.1 million, consuming 81.9% of total revenues. This R&D intensity is among the highest in the biotechnology sector and reflects the company's aggressive oncology pipeline investment. The R&D split shows $257.2 million for COVID-19 programs (down 25% YoY) and $2199.8 million for non-COVID programs (up 37.3% YoY), with oncology consuming the vast majority. Sales, general and administrative expenses increased 7.4% to $652.9 million, driven by commercial IT platform investments and headcount growth. Other operating result was negative $731.3 million, compared to negative $204.9 million in 2023, primarily due to settlement of contractual disputes and litigation expenses. The finance result was positive $746.3 million, up from $367.1 million in 2023, driven by interest income on the substantial cash reserves. Income from profit transfer totaled $337.4 million, and other interest and similar income contributed $699.1 million. Despite the operating loss, the strong finance result partially offset the deficit, resulting in the pre-tax loss of $1237.4 million. Income taxes provided a $7.3 million benefit, leading to the net loss of $1230.1 million on a standalone basis and $725.2 million on a consolidated basis. The difference reflects subsidiary profitability and consolidation adjustments. Cash and cash equivalents plus security investments totaled $19.0 billion as of December 31, 2024, down modestly from the prior year as cash burn was partially offset by investment returns. Total current assets were $22.1 billion, against total current liabilities of $2.5 billion, yielding a current ratio of 8.8—exceptional liquidity that provides substantial operational runway. Total equity stood at $23.9 billion, with minimal debt (total debt-to-equity of 1.62%). The balance sheet is fortress-like, but the income statement shows a company in heavy investment mode. For 2025, BioNTech has guided total revenues between $1.9 billion and $2.4 billion, implying a further 20-38% decline. The company explicitly states it does not expect positive net income in 2025. At the guided revenue midpoint of $2.1 billion and maintaining R&D at approximately $2.5 billion, the company would burn approximately $1.1-1.2 billion in cash annually, suggesting the $19.0 billion reserves provide 14-17 years of runway at current rates. However, this calculation assumes no additional acquisitions, no significant litigation payments, and stable investment returns—assumptions that may not hold. The financial narrative is therefore one of deliberate, aggressive reinvestment of pandemic-era cash flows into oncology development, with the market capitalization of $22.7 billion reflecting investor skepticism about whether this investment will generate approved products before the cash depletes.